Phase 2 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with type 1 or type 2 diabetes, with a blood sugar control measurement (HbA1c) below 12%, and whose diabetes medication has been stable for at least 30 days before the study starts, with no major medication changes planned
- People who have a specific type of eye swelling related to diabetes (called centre-involved diabetic macular edema) confirmed by a specialised eye scan, with the swelling in the central part of the retina measuring at or above a certain thickness (320 µm) in the eye being studied
- People whose vision in the study eye falls within a specific range — roughly between 20/320 and 20/32 on a standard eye chart — as measured at the screening visit
- Additional inclusion criteria may apply (confirm with trial site)
Who may not be able to join:
- People whose macular swelling in the study eye is caused by something other than diabetic macular edema
- People who have advanced diabetic eye disease with abnormal new blood vessel growth in the study eye, including growth on the iris or in the front part of the eye
- People who have received certain injections into the eye (anti-VEGF treatments) within the past 4 to 6 months (depending on the specific medication used), or who have had more than 4 of these injections in total in the study eye
- People who have previously had laser treatment to the retina, surgery inside the eye, steroid injections in or around the eye within the past 12 months, certain slow-release steroid implants at any time, or steroid or anti-inflammatory eye drops within the past 30 days
- People who have active eye inflammation, or a history of inflammation inside the eye within the past year
- People who are missing the natural lens of the eye or the membrane that holds it in place (certain exceptions may apply — confirm with trial site)
- Additional exclusion criteria may apply (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-800-243-0127
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence (yes/no) of a gain of ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with baseline in the study eye at Week 48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.